Lanifibranor

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Phase 2b Study in NASH to Assess IVA337

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Liskiewicz D, Novikoff A, Khalil A et al.

Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.

Zhao S, Tian F, Yu L et al.

An Extravascular Synergistic Cocktail Therapeutic Strategy Based on Lanifibranor Loaded Self-Healing Bioelastomer for Abdominal Aortic Aneurysms.

Hu J, Dai W, Xu Z et al.

Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.

Holleboom AG, Francque SM, Cusi K et al.

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.

Ahmed T, Farooq S, Naveed MA et al.